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ABSTRACT
Peripheral blood hematopoietic stem cell (PBSC) transplants have been shown to result in more rapid engraftment
than standard bone marrow transplants (BMTs). Little comparative data exist regarding complications in patients
receiving transplants using these stem cell sources. In our study, 97 adults with advanced hematologic malignancies
who received allogeneic PBSC transplants were compared with 97 adults who received allogeneic BMTs using
identical preparative regimens and support parameters. The incidence of systemic infections and other major
complications occurring within the first year after transplantation were calculated in both groups. Proportional
hazard analysis was used to examine risk factors for death and complications in both groups. Patients receiving PBSC
transplants had more rapid neutrophil (17 days versus 24 days; P < .001) and platelet engraftment (28 days versus 47
days; P < .001) than BMT recipients. The survival rate at 2 years was 38% in PBSC transplant recipients and 28%
in marrow recipients (P  .08). There was no difference in rates of grade II to IV acute graft-versus-host disease
(GVHD) between groups (PBSC 46%, BMT 51%; P  .3). PBSC transplant recipients were more likely to develop
chronic GVHD after 180 days (hazard ratio 2.2; P  .05). Accompanying this “late-onset chronic GVHD,” a pattern
of more frequent late systemic fungal and cytomegalovirus infections was observed in PBSC transplant recipients. In
conclusion, although PBSC transplant recipients engraft more quickly than BMT recipients and have somewhat
better 2-year survival rates, they develop more frequent late-onset chronic GVHD and may have more late fungal and
cytomegalovirus infections than marrow recipients. Further studies must examine this late-onset chronic GVHD and
better characterize immune reconstitution in PBSC transplant recipients to understand their effects on patient
recovery.
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INTRODUCTION
Peripheral blood stem cells (PBSC) are increasingly being
used in allogeneic transplantation. Although the ﬁrst report
describing the use of PBSC for allogeneic transplantation ap-
peared in 1989 [1], case series demonstrating its feasibility in the
allogeneic setting did not appear until the mid-1990s [2-4].
In 1999, 34% of all transplantations reported to the Inter-
national Bone Marrow Transplant Registry (IBMTR) used
PBSC (IBMTR, personal communication, 2001), whereas in
2000 this percentage increased to 43%. Most allogeneic PBSC
transplantations reported to date have involved matched sibling
donors, although experience with unrelated donor transplanta-
tions is increasing as well [5,6].
Despite the rapid acceptance of PBSC for transplantation,
only recently have data from randomized trials [7-12] and large
registry-based data [13] become available. These studies dem-
onstrate more rapid neutrophil and platelet engraftment in
PBSC transplant recipients, with both cell lines recovering ap-
proximately 5 to 6 days earlier. In addition, a large randomized
trial [11] found that PBSC transplant recipients had a trend
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toward better 2-year survival rate than bone marrow transplant
(BMT) recipients. In no randomized trials have PBSC trans-
plant recipients had worse survival rates than BMT recipients,
although small numbers of patients and short observation peri-
ods have limited our ability to draw deﬁnitive conclusions.
With regard to complications of PBSC and BMT, existing
studies have compared graft-versus-host disease (GVHD) inci-
dence and severity between groups but have provided little
information regarding other complications. One trial [9] and a
large registry analysis [13] have found higher rates of chronic
GVHD in PBSC transplant recipients. A meta-analysis of com-
parative studies found slightly more acute GVHD in PBSC
transplant recipients [14], although no individual study was able
to detect any difference between groups. We have analyzed the
major posttransplantation complications occurring in a group of
PBSC transplant recipients and a comparable cohort of BMT
recipients.
METHODS
All patients included in this study received related donor
hematopoietic stem cell transplants at the University of Minne-
sota between January 1990 and June 2000. The cohort of pa-
tients receiving HLA-matched PBSC transplants was enrolled
on a single protocol for high-risk malignant disease between
1995 and 2000. A comparison cohort of BMT recipients was
identiﬁed from the University of Minnesota Bone Marrow
Transplant database, which contains prospectively collected data
on all patients who have undergone transplantation at our in-
stitution. Additional information on platelet recovery, infectious
complications, and other complications was obtained by chart
review. BMT recipients with sibling donors older than 12 years
of age who received transplants between January 1990 and June
2000 for diseases other than chronic myelogenous leukemia
(CML) in ﬁrst chronic phase or non-malignant disease were
included in the comparison cohort. Written informed consent
was obtained from all patients and donors, and the study was
approved by the Committee on the Use of Human Subjects in
Research for the University of Minnesota.
Donor PBSC were mobilized with granulocyte colony-
stimulating factor (G-CSF) given subcutaneously at 7.5 g/
kg/d. Collections began on day 5 of mobilization using a Fenwal
CS-3000 PLUS cell separator (Baxter, Round Lake, IL, USA) as
previously described [15]. CD 34 cell counts in the apheresis
products were determined by ﬂow cytometry and, as needed,
consecutive daily collections were performed to harvest the
target CD34 cell dose of 5  106/kg recipient weight. Bone
marrow harvests were performed with the target nucleated cell
dose of 2.0  108/kg recipient body weight.
All PBSC and BMT recipients were conditioned with cy-
clophosphamide (60 mg/kg/d  2) and total body irradiation
(TBI 1320 cGy given as 165 cGy fractions twice daily for 4
days). PBSC or marrow were infused on the day of collection
without cryopreservation or other manipulation. All patients
received GVHD prophylaxis with cyclosporine and short-course
methotrexate [16]. G-CSF was administered at 5 g/kg/d to
PBSC transplant recipients from day 1 until neutrophil recov-
ery (2.5  109/L on 2 consecutive days). BMT patients re-
ceived hematopoietic growth factors only if they failed to dem-
onstrate an absolute neutrophil count (ANC)  5.0  108/L by
day 21.
Transfusion support using irradiated blood products was
provided to maintain a hemoglobin  8.0 g/dL and to prevent
severe thrombocytopenia ( 20  109/L until 1997 and  10 
109/L thereafter). Cytomegalovirus (CMV) seronegative pa-
tients received CMV safe transfusion support (from either se-
ronegative donors or by ﬁltration leukodepletion). Anti-infec-
tive prophylaxis included trimethoprim sulfa double strength
twice daily from the onset of conditioning until initiation of
broad anti-bacterial therapy and then double strength twice
daily, twice a week thereafter. Fluconazole was used daily for
antifungal prophylaxis and nystatin was added for patients col-
onized with azole resistant yeasts (C. krusei or C. glabrata).
Febrile neutropenia was managed with vancomycin (for 72
hours) along with ceftazidime  aminoglycosides. Beginning in
1999, ciproﬂoxacin was substituted for trimethoprim sulfa from
the onset of conditioning until neutrophil recovery as additional
gram negative prophylaxis. Amphotericin was added for persist-
ing febrile neutropenia unresponsive to broad spectrum antibi-
otics. Patients were nursed in private rooms using HEPA air
ﬁltration and rapid air exchange (12-15 air exchanges/h) and
positive pressure isolation throughout the period of neutrope-
nia. Strict hand washing, isolation, and masks for visitors or staff
with suspected upper respiratory infections were universal pre-
cautions. When out of their rooms, patients wore tight ﬁtting
HEPA equivalent ﬁltration masks at all times while neutropenic
and following engraftment, when in crowds, or within the hos-
pital complex.
Neutrophil engraftment was deﬁned as the ﬁrst of three
consecutive days when the ANC was greater than 5.0  108/L
for 3 consecutive days. Platelet recovery was deﬁned as the ﬁrst
day in which the patient’s platelet count was 20  109/L
without transfusion support for 7 days. Infectious complications,
including pneumonia, bacteremia, viremia, and fungal infec-
tions, were identiﬁed from the research database and veriﬁed by
independent chart review. Rates of bacteremia and pneumonia
were calculated at 100 days, whereas rates of infections that
frequently occur after 100 days such as cytomegalovirus (CMV)
disease and fungal infections were calculated at both 100 days
and 1 year.
Non-infectious complications were reviewed and included
for analysis. Non-infectious pneumonitis was deﬁned as inﬁl-
trates on chest x-ray or computed tomography (CT) scan with-
out documented infection. Hepatic veno-occlusive disease
(VOD) was designated in any patient who had clinical and
ultrasound evidence of VOD or a total bilirubin 10 mg/dL at
any time posttransplantation along with a compatible clinical
presentation. Hemodialysis for any length of time posttrans-
plantation was used to deﬁne renal failure. GVHD was deﬁned
according to standard criteria [17], with histopathological con-
ﬁrmation where possible. All prospectively collected staging and
grading data were reviewed for ﬁnal GVHD grade assignment
by one clinician (D.W.).
All statistics were performed using SAS for Microsoft Win-
dows version 8.0 (SAS Institute, Cary, NC, USA). Statistical
comparisons of patient and transplant characteristics between
the PBSC and BMT recipients were performed using the gen-
eral Wilcoxon test (age, time from diagnosis to transplantation,
neutrophil level, and platelet engraftment), Pearson’s chi-square
test (sex and CMV serology), and Fisher exact test (diagnosis and
year of transplantation) [18]. The probability of overall survival
was estimated with Kaplan-Meier analysis [19]. Equality of these
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curves was compared with the Wilcoxon test. The cumulative
incidence of engraftment, acute and chronic GVHD, and other
complications (i.e., bacteremia, systemic fungal infections, CMV
disease, infectious pneumonia, non-infectious pneumonitis, he-
modialysis, and VOD) was calculated by treating deaths from
other causes as competing risks [20]. Statistical comparisons of
the cumulative incidence of complications between groups were
completed with the Wilcoxon test.
Multivariate proportional hazard analyses for survival, re-
lapse, GVHD, and major complications at 100 days were per-
formed in SAS with the forward stepwise procedure [21]. Prior
to all analyses, proportional hazard assumptions were tested and
met in the two groups. Candidate risk factors included in the
models were stem cell source, time to ANC  5.0  108/L,
high-risk disease status (all diseases except CML chronic phase
and AML in ﬁrst or second remission), recipient age, recipient
CMV status, and recipient sex. Only those alive without chronic
GVHD at 180 days were included for proportional hazard
analysis of late-onset chronic GVHD.
RESULTS
Patient and Donor Characteristics
A total of 97 patients received PBSC transplants between
January 1996 and June 2000. These patients were compared
with 97 patients who received BMTs between 1990 and 2000.
Demographic characteristics for these patients are shown in
Table 1. There were several statistically signiﬁcant differences
in these characteristics between the two groups. Patients receiv-
ing PBSC transplants were older on average than BMT recipi-
ents (44 versus 39 years). PBSC transplant recipients were more
likely to receive transplants for Non-Hodgkin’s lymphoma
(NHL), chronic lymphocytic lymphoma (CLL), and multiple
myeloma (MM). Marrow recipients were more likely to have
Table 1. Patient and Donor Characteristics
PBSC Marrow P
Number of patients 97 97
Median age, y (range) 44 (17-60) 39 (16-59) <.001
Sex (recipient:donor)
Female:female 24 24 .19
Female:male 13 24
Male:female 27 25
Male:male 33 24
Disease and stage
Myeloid diseases .39
AML
CR1 4 2
CR2 or greater 6 14
Relapse 10 20
MDS 17 25
CML
Chronic phase 2 0
Accelerated phase 5 25
Blast crisis 0 1
Second chronic phase 4 4
Myelofibrosis 1 1
Lymphoproliferative disorders .009
CLL 7 1
Plasma cell leukemia 2 1
Lymphoma
Hodgkin’s 1 2
Low-grade non-Hodgkin’s lymphoma 14 0
Intermediate-grade non-Hodgkin’s lymphoma 0 0
High-grade non-Hodgkin’s lymphoma 10 1
Mantle cell 5 0
Multiple myeloma 9 0
Median time from diagnosis to transplantation (mo) 13.9 (1-150) 7.2 (1-88) <.001
Year of transplantation
1990-1995 0 87 (95%) <.001
1996-2000 97 (100%) 10 (5%)
CMV serology .42
Recipient (), donor () 25 27
Recipient (), donor () 16 10
Recipient () 56 60
Median nucleated cell dose (108/kg) 8.14 (3.1-19.74) 2.0 (0.6-3) <.001
Median CD34 cell dose (106/kg) 6.57 (1.92-15.0) 1.76 (0.56-14.2)* <.001
*n  12.
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undergone transplantation for CML or myelodysplastic syn-
drome (MDS).
The median time from diagnosis to transplantation was
different in patients receiving PBSC transplants (13.9 months)
as compared with those receiving BMTs (7.1 months), as was the
year of transplantation, with 100% of PBSC transplant recipi-
ents undergoing transplantation between 1996 and 2000 but
10% of marrow recipients receiving transplants during the same
period (p .001 for both). CMV serostatus was not signiﬁcantly
different between patients in both groups.
Median nucleated cell counts were 8.4  108/kg and 2.0 
108/kg in PBSC and marrow grafts, respectively (P .001). The
median CD34 count in PBSC allografts was 6.57  106/kg
(n  97); in marrow allografts the median CD34 count was
1.76  106/kg (n  12) (P  .001). The median allograft CD3
count in PBSC transplant recipients was 2.25 108/kg (n 67).
The majority of PBSC donors required only 1 (45%) or 2 (40%)
collections. Three or 4 collections were required for 8% and 6%
of donors, respectively.
Engraftment
Neutrophil recovery is shown in Figure 1. The median time
to an ANC  5.0  108/L for 3 consecutive days was 17 days in
the PBSC transplant recipients versus 24 days in marrow recip-
ients (P  .001). A larger CD34 cell dose was not associated
with more rapid neutrophil recovery in PBSC patients (P  .5).
Platelet recovery data were available in all PBSC transplant
recipients and in 80 (82%) marrow recipients. Median time to
platelet recovery was 28 days in PBSC transplant recipients and
47 days in BMT recipients (P  .001). Marrow patients for
whom platelet data were not available had similar neutrophil
engraftment as those for whom data were available (26 versus 25
days, respectively; P  .5).
GVHD
Acute GVHD rates were comparable between groups (Fig-
ure 2). At 100 days, 46% (95% conﬁdence interval [CI]: 36%-
57%) of PBSC transplant recipients and 51% (95% CI: 39%-
62%) of BMT recipients developed grade II to IV GVHD (P 
.3). Rates of grade III to IV GVHD were 15% (95% CI:
8%-23%) and 16% (95% CI: 9%-24%), respectively (P  .7).
As shown in Table 2, the distribution of organ involvement and
the stage of acute GVHD was similar in BM and PBSC trans-
plant recipients (i.e., skin disease in 95% and 82% of patients
[P  .8]; gastrointestinal involvement in 44% and 31% of
patients [P  .5]; and liver in 17% and 12% of patients [P  .6],
respectively). Incidence of chronic GVHD at 1 year (Figure 3)
was 37% (95% CI: 27%-47%) in PBSC transplant recipients
and 28% (95% CI: 20%-37%) in marrow recipients (P  .7). In
multivariate modeling, no other factors were signiﬁcantly asso-
ciated with the development of acute or chronic GVHD. In
PBSC transplant recipients chronic GVHD continued to occur
beyond 6 months after transplantation (“late-onset chronic
GVHD”). PBSC transplant recipients were 2.2 times as likely as
marrow recipients to develop late-onset chronic GVHD (Figure
3) (P  .05). This excess risk of late-onset chronic GVHD was
age-dependent. In patients aged younger than 45 years, PBSC
transplant recipients had a 2.2-fold excess risk (P  .13) of
late-onset chronic GVHD whereas those aged older than 45
years had essentially the same risk of developing late-onset
GVHD (hazard ratio [HR] 1.01; P  .99).
Some series have suggested that higher CD34 graft counts
result in a higher risk of developing GVHD [22]. Neither the
infused CD3 nor CD34 allograft dose had any correlation with
rates of acute or chronic GVHD. For patients with the highest
quartile of CD34 graft cell counts (9.5-15.0  106 CD34/kg),
the HR for developing grade II to IV acute GVHD was 0.8
compared with the bottom three quartiles (P  .7). For chronic
GVHD, this HR was 1.3 (P  .5). Likewise, for patients with
CD3 graft cell counts in the highest quartile (3.3  108 CD3/
kg), the HR for grade II to IV acute GVHD was 0.7 (P  .6),
whereas for chronic GVHD this HR was 1.1 (P  .8).
Other Complications
We examined the major posttransplantation complication
rates for both PBSC and marrow recipients (Table 3). The
cumulative incidence of bacteremia at 100 days was 35% in
PBSC transplant recipients and 43% in marrow recipients (P 
.02). For gram-positive bacteremia, rates at 100 days were 28%
in PBSC transplant recipients and 39% in marrow recipients
(P  .01) and for gram-negative bacteremia rates were 18% and
22%, respectively (P  .15).
Figure 1. Time to ANC greater than 5.0  108/L for PBSC transplant
and BMT recipients.
Figure 2. Cumulative incidence of grades II to IV acute GVHD in
PBSC transplant and BMT recipients.
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We observed a consistent pattern suggesting higher rates of
late infections in PBSC transplant recipients . At 100 days, 24%
of PBSC transplant recipients and 24% of marrow recipients
had developed systemic fungal infections (P  .82). During the
interval between days 100 and 365, these rates were 18% for
PBSC versus 10% for BM (P  .2).
A similar pattern was found in CMV disease. At 100 days,
CMV infections had occurred in 18% of PBSC transplant re-
cipients and 21% of marrow recipients. Late-onset CMV infec-
tions (day 100-365) were somewhat more common in PBSC
transplant recipients, occurring at a rate of 20% compared with
a rate of 10% in marrow recipients (P  .18).
Infectious pneumonia occurred in 4% of PBSC transplant
recipients and 9% of marrow recipients at 100 days (P  .14).
No signiﬁcant differences were observed in the rates of non-
infectious pneumonia, hemodialysis, and hepatic VOD between
groups.
Analysis of Risk Factors for Complications
To adjust for factors in addition to stem cell source that
were predictive of complications, we performed proportional
hazard analyses of potential risk factors for complications (Table
4). For bacteremia, use of BM as a stem cell source was found to
be predictive with a HR of 1.65 relative to PBSC (P  .01).
Similarly, BM transplantation was associated with gram-positive
bacteremia, HR of 1.62 (P  .02). For CMV disease, recipient
CMV serostatus and high-risk disease were found to be signif-
icant in a multivariate model, with HRs of 16.7 (P  .001) and
2.4 (P  .06), respectively. Longer time to neutrophil recovery
demonstrated a trend toward more frequent infectious pneumo-
nia, with a HR of 1.2 per 5 days of neutropenia (P  .06). Time
to neutrophil recovery was not associated with any other com-
plication. No factors were signiﬁcant in models examining risks
for acute or chronic GVHD, gram-negative bacteremia, sys-
temic fungal infection, non-infectious pneumonia, renal failure,
or hepatic failure/VOD. The stem cell source was not associated
with different risks of any of these complications.
Relapse and Survival
Because use of PBSC was initiated in 1995, the median
follow-up was shorter, 30 months in PBSC transplant recipients
versus 88 months in BMT recipients. There was no difference in
the cumulative incidence of malignant relapse at 2 years, with
rates of 23% (14%-31%) in PBSC transplant recipients and
Table 2. Severity and Sites of Acute GVHD
Severity
Skin GI Liver
PBSC
N (%)
Marrow
N (%)
PBSC
N (%)
Marrow
N (%)
PBSC
N (%)
Marrow
N (%)
Grade I 12 (21) 14 (22) — — — —
Grade II 25 (44) 30 (48) 13 (23) 20 (32) — —
Grade III 8 (14) 14 (22) 2 (4) 6 (10) 5 (9) 9 (14)
Grade IV 2 (4) 2 (3) 3 (5) 2 (3) 2 (4) 2 (3)
Figure 3. Cumulative incidence of chronic GVHD overall follow-up and after 180 days (inset).
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18% (10%-25%) in marrow recipients (P  .89). For each
cohort, we calculated survival rates at 30 days, 100 days, and 2
years. At 30 days, survival was estimated to be 85% (95% CI:
77%-92%) for marrow recipients and 87% (95% CI: 80%-93%)
for PBSC transplant recipients (P  .70). At 100 days, 60%
(95% CI: 50%-69%) of marrow recipients survived as opposed
to 72% (95% CI: 63%-81%) of PBSC transplant recipients (P
.09). At 2 years, 28% (95% CI: 19%-37%) of marrow and 38%
(95% CI: 26%-50%) of PBSC transplant recipients survived
(P  .08) (Figure 4).
Analysis of Risk Factors for Relapse and Mortality
No risk factors, including high-risk disease, were found to
be signiﬁcantly associated with relapse in a model including both
PBSC and marrow recipients (Table 5). In a multivariate model
of survival, use of marrow (HR 1.4; P  .05) and older recipient
age (HR 1.02 per year of age; P  .03) were signiﬁcant risk
factors associated with higher mortality. Neither diagnosis, risk
group, nor CMV serology were independent factors associated
with mortality. In an attempt to determine whether rates of
death differed over time, we performed an adjusted multivariate
analysis of HRs for death over various time intervals. We ob-
served a higher HR for death in BM recipients between day 30
and 100 (marrow HR 1.8; P  .06) whereas mortality rates were
nearly identical before day 30 (HR 1.2; P .7), between day 100
and day 365 (HR 1.3; P  .4), and beyond 1 year (HR 0.7;
P  .5).
DISCUSSION
As reported, our study suggests that PBSC transplants lead
to more rapid engraftment than BMT [7-11]. Whether more
rapid neutrophil engraftment offers any more lasting clinical
advantages for PBSC transplant recipients is not as clear because
some data suggest fewer serious early infections [12]. We ob-
served that PBSC grafts result in fewer episodes of bacteremia in
the early posttransplantation phase, due primarily to lower rates
of gram-positive bacteremia (mostly staphylococci and strepto-
cocci). However, the rate of late-onset fungal and CMV infec-
tions occurring in PBSC transplant recipients between 100 days
and 1 year was roughly twice that of marrow recipients. In the
current series, we found no difference in rates of acute GVHD
but observed a trend to greater risks of late-onset chronic
GVHD developing between 6 and 24 months posttransplanta-
tion, especially in younger patients.
Similar data conﬁrming more acute GVHD in PBSC trans-
plant recipients is limited. Although all trials showed slightly
more acute GVHD with PBSC, no individual randomized trial
has found a signiﬁcant difference. Similarly, the result of a large
registry analysis has found no difference in rates of acute
GVHD. A recent meta-analysis of comparative studies, how-
ever, demonstrated a slightly increased risk of acute GVHD in
PBSC transplant recipients (RR 1.16; P  .006) compared with
Table 3. Major Posttransplantation Complications: Cumulative Incidence
at 100 Days Unless Noted
Complication
PBSC %
(95% CI)
Marrow %
(95% CI) P
Bacteremia 35% (26-44) 43% (34-53) .02
Gram-positive 28% (19-36) 39% (30-48) .01
Gram-negative 18% (10-25) 22% (14-30) .15
Systemic fungal infection
100 d 24% (16-31) 24% (16-32) .82
1 y 32% (23-40) 28% (19-36) .69
CMV disease
100 d 18% (11-25) 21% (14-29) .87
1 y 28% (19-36) 25% (16-33) .77
Infectious pneumonia 4% (0-8) 9% (3-14) .14
Non-infectious pneumonitis 7% (2-12) 7% (2-12) .89
Hemodialysis 11% (6-17) 10% (5-15) .69
Hepatic toxicity/VOD 3% (0-6) 7% (2-11) .45
Table 4. Multivariate Analysis of Risk Factors for Complications
Event Adverse Factor HR P
Bacteremia Stem cell source
(marrow)
1.70 (1.08-2.7) .02
Time to neutrophil
recovery
0.98 (0.85-1.2)* .77
Gram-positive
bacteremia
Stem cell source
(marrow)
1.6 (1.0-2.4) .05
Time to neutrophil
recovery
1.0 (0.87-1.2)* .86
CMV disease Recipient CMV
status ()
16.7 (6.0-46.3) <.0001
High-risk disease 2.4 (0.96-6.1) .06
Stem cell source
(marrow)
0.97 (0.5-1.7) .9
Time to neutrophil
recovery
1.03 (0.86-1.25)* .7
Infectious
pneumonia
Time to neutrophil
recovery
1.2 (1.0-1.6)* .06
*HR/5 d of neutropenia.
Figure 4. Probability of survival in the study groups.
Table 5. Multivariate Analysis of Risk Factors for Survival
Risk Factor HR P
Recipient age 1.23 (1.02-1.5)* .03
Stem cell source (marrow) 1.43 (1.01-2.1) .05
*Reﬂects increased hazard per decade of age.
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marrow recipients, suggesting that a small incremental differ-
ence may exist [14].
The evidence documenting more chronic GVHD in PBSC
transplant recipients is stronger, but estimates as to the degree
of difference between groups are limited by relatively short
observational periods. PBSC transplant recipients have been
found to have more chronic GVHD in larger series such as the
IBMTR analysis [13] and the meta-analysis of comparative stud-
ies [14]. Additionally, one randomized trial found a clear differ-
ence in chronic GVHD [9], but some [11] have suggested that
GVHD prophylaxis was suboptimal in this series. Updates to the
IBMTR analysis have shown persistently increased rates of
chronic GVHD in PBSC patients to a median follow-up of 5
years [23]. In most analyses, the continuing risks of developing
chronic GVHD in PBSC transplant recipients persist until 12 or
15 months posttransplantation whereas risks in marrow recipi-
ents appear to plateau earlier [9,11,13]. The age-dependence of
later-onset chronic GVHD has not been examined in other
series.
In our series, PBSC transplant recipients demonstrated a
trend toward improved survival over marrow recipients, with
superior age-adjusted 2-year survival rates improved in PBSC
transplant recipients. Survival between groups was similar at
30 days posttransplantation, but the modest advantage of
PBSC became apparent by 100 days. Beyond 100 days, the
mortality rates in the 2 cohorts were similar and persisted
throughout the length of follow-up. As in most studies of
allogeneic transplantation, older patients were more likely to
have poor outcomes. In our series, differences in demo-
graphic characteristics between the 2 groups suggest caution
about these conclusions.
The late-onset fungal and viral infectious risk we found in
PBSC transplant recipients may reﬂect the risk of continuing
chronic GVHD or of delayed full immune reconstitution. Al-
though our study cannot clarify the etiology of this late infec-
tious risk after PBSC transplantation, virtually all patients with
these late-onset systemic infections had developed chronic
GVHD. Earlier studies including the 5 randomized trials pub-
lished to date have not examined this late infectious risk, and
thus additional studies will be required to corroborate these
ﬁndings.
These increased risks of later-onset opportunistic infections
in PBSC transplant recipients will require detailed study of the
comparative kinetics and completeness of immune reconstitu-
tion after PBSC transplantation or BMT. The deﬁnitive choice
of the preferred stem cell source may necessitate later re-analysis
of larger series to insure consideration of late infections and
their morbidity following peripheral blood allogeneic transplan-
tation.
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